Sperogenix Therapeutics is a platform focusing on development and commercialization of Rare Diseases Medications in China , provide clinically accessible products for rare disease patients and successful commercial solutions for rare disease therapeutics in China.
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
Sperogenix will have the exclusive right to develop, manufacture and commercialize ABSK021 in mainland China, Hong Kong SAR and Macao SAR for non-oncology rare neurological diseases indications.
Minoryx and Sperogenix ink an exclusive license agreement to develop and commercialize leriglitazone in China
Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.
Mr. Ziyu YAN delivered a keynote speech at the 9th China Rare Disease Summit
Mr. Yan Zhiyu was invited to attend the 9th China Rare Disease Summit held in Chengdu on 12 September and delivered a keynote speech on promoting China's participation in international multi-center clinical trials to accelerate orphan drugs access to China.